Key Points
- CEO Laurent Fischer purchased 117,614 shares on Dec. 8 at an average price of $4.31 (≈$506,916), bringing his total stake to 201,513 shares — a 140.19% increase; the transaction was disclosed on an SEC Form 4.
- Adverum shares trade near $4.36 with a market cap of about $96.3M; the company reported a quarterly EPS of -$2.03 (missing estimates) and the street consensus rating is a Hold with an average target of $10.50.
Adverum Biotechnologies, Inc. (NASDAQ:ADVM - Get Free Report) CEO Laurent Fischer bought 11,085 shares of the company's stock in a transaction that occurred on Friday, December 5th. The shares were bought at an average price of $4.24 per share, for a total transaction of $47,000.40. Following the completion of the acquisition, the chief executive officer owned 83,899 shares in the company, valued at approximately $355,731.76. This trade represents a 15.22% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Laurent Fischer also recently made the following trade(s):
- On Monday, December 8th, Laurent Fischer purchased 117,614 shares of Adverum Biotechnologies stock. The stock was bought at an average price of $4.31 per share, with a total value of $506,916.34.
Adverum Biotechnologies Stock Up 2.3%
Shares of NASDAQ:ADVM opened at $4.36 on Tuesday. The company has a market capitalization of $96.26 million, a price-to-earnings ratio of -0.51 and a beta of 0.87. The company has a 50 day moving average of $4.41 and a two-hundred day moving average of $3.35. Adverum Biotechnologies, Inc. has a 52-week low of $1.78 and a 52-week high of $6.12.
Adverum Biotechnologies (NASDAQ:ADVM - Get Free Report) last posted its earnings results on Wednesday, November 12th. The biotechnology company reported ($2.03) EPS for the quarter, missing analysts' consensus estimates of ($1.80) by ($0.23). On average, equities analysts anticipate that Adverum Biotechnologies, Inc. will post -4.92 earnings per share for the current year.
Institutional Trading of Adverum Biotechnologies
Institutional investors and hedge funds have recently bought and sold shares of the stock. Y Intercept Hong Kong Ltd purchased a new stake in Adverum Biotechnologies during the second quarter valued at about $45,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Adverum Biotechnologies during the third quarter valued at approximately $58,000. XTX Topco Ltd purchased a new stake in shares of Adverum Biotechnologies in the 2nd quarter valued at approximately $64,000. Qube Research & Technologies Ltd acquired a new position in Adverum Biotechnologies in the 2nd quarter worth approximately $66,000. Finally, Marshall Wace LLP purchased a new position in Adverum Biotechnologies during the 2nd quarter worth approximately $107,000. Institutional investors and hedge funds own 48.17% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms have weighed in on ADVM. Weiss Ratings reissued a "sell (d-)" rating on shares of Adverum Biotechnologies in a research report on Wednesday, October 8th. Chardan Capital cut Adverum Biotechnologies from a "strong-buy" rating to a "hold" rating in a research note on Monday, October 27th. Truist Financial set a $5.00 price objective on Adverum Biotechnologies in a research note on Friday, October 24th. HC Wainwright restated a "neutral" rating and set a $5.00 price objective (down from $30.00) on shares of Adverum Biotechnologies in a report on Monday, November 17th. Finally, Mizuho set a $5.50 target price on Adverum Biotechnologies in a research note on Wednesday, October 29th. One analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Adverum Biotechnologies currently has an average rating of "Hold" and an average price target of $10.50.
View Our Latest Report on ADVM
Adverum Biotechnologies Company Profile
(
Get Free Report)
Adverum Biotechnologies, Inc, a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
